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Introduction
The application of microRNAs (miRNAs), small single-stranded noncoding RNAs of 18 to 24 bases in length, that function in the transcriptional and post-transcriptional regulation of target gene expression by repressing the 3′UTR of mRNA, 1, 2 may provide a novel option to attenuate the progression of kidney disease. miRNAs were originally considered the product of 'junk DNA', however, more than 2000 miRNAs have that now been identified, 3 that are involved in the regulation of approximately 30% of all mammalian protein encoding genes that have diverse roles in the cell cycle, apoptosis, tissue development, stem cell division and development of degenerative disease. 4, 5 _ENREF_5 In particular, dysregulation of miRNAs has been implicated in diseases associated with kidney homeostasis including polycystic kidney disease, diabetic nephropathy and kidney cancer [reviewed 6 ].
The characterization and roles of miRNAs in both anti-fibrotic and pro-fibrotic settings of kidney disease have been reported. 2, 7 _ENREF_7 We 8 and others 9 have identified the functional roles of the miR-let7 family members (miR-let7b and miR-let7c) in renal fibrosis resulting from diabetes mellitus, through regulation of transforming growth factor-β (TGF-β) signalling. 8 Profiling of human renal proximal tubule (HK2) cell miRNAs demonstrated that miR-let7c was downregulated under fibrotic conditions, 9 suggesting that miR-let7 may have clinically relevant therapeutic potential to repair or reverse established kidney fibrosis. However, the successful delivery of miRNA to the site of injury remains a significant challenge in the field. delivery vehicle for therapeutic miRNA treatment, due to their ability to specifically target inflammation in neurodegenerative disorders, and an ability to transfer molecules via exosomal trafficking, 10 Exosomes can be loaded with miRNAs, which transfer to neighbouring cells or to targeted cells, leading to the repression of target gene expression. 11, 12 A recent study using prion-infected neuronal cells and deep sequencing detected a distinct exosome-specific miRNA signature. 13 This novel mechanism of intercellular communication mediated via exosomes also was demonstrated using siRNA as a marker to track exocytic and endocytic pathways. 14 MSCs secrete microparticles or exosomes enriched with pre-miRNAs 15 , and the miRNA expression profile of human
MSCs is associated with a high expression of the miR-let7 family 16 suggesting that miRlet7 derived from MSCs may play a protective role in tissue injury and disease. These studies suggest that an exosome-based miRNA delivery may provide a clinically relevant gene-therapy strategy for the treatment of fibrotic kidney disease.
MSCs have demonstrated safety in both completed and ongoing clinical trials [17] [18] [19] including kidney transplantation 20, 21 and exhibit innate therapeutic effects in heart attacks and respiratory disease. 22, 23 These immunoprivileged cells rapidly home to injured kidneys 24 and release cytokines that promote repair through effects on regulatory immune cells 25 and alteration of macrophage phenotype. 26 They can prevent and/or reverse kidney fibrosis and improve renal function in both experimental models 27-29 and human patients. 
ACCEPTED ARTICLE PREVIEW
The current study uses an innovative strategy to construct a miR-let7 delivery system that utilises genetically engineered MSCs, transduced to overexpress miR-let7c (miR-let7c-MSC), as a therapeutic tool to target kidney disease. In a mouse model of unilateral ureteral obstruction (UUO), miR-let7c was selectively delivered to the injured kidney following administration of MSC-miR-let7c, where an elevated expression of kidney miR-let7 corresponded with improved kidney structure and reduction of interstitial collagen, compared to delivery of non-targeting control (NTC) MSCs. In vitro analysis using the addition of isolated exosomes or indirect co-culture confirmed that miR-let7c-MSCs induced an increased expression of the target miRNA (let7c) in neighboring rat 
MSC exosomal delivery of miR-let7c into kidney cells
To assess the transfer of miR-let7c expression from MSCs, the exosomes from culture media of modified MSC were isolated and assessed over 72 hours of culture using a miRlet7c assay. In comparison with isolated exosomes obtained from NTC-MSC culture medium, miR-let7c expression in exosomes from miR-let7c-MSC medium was significantly increased (P<0.05; Figure 3a ) suggesting that miR-let7c expression was increased and exocytosed via MSC-derived exosomes. The expression of miR-let7a and let7d showed no significant change (Supplementary Figure 2) . To avoid the effect of viral transduction of other miRNA, the endogenous miR-218 from engineered MSC was assayed as a negative control miRNA, which has previously been identified in MSCs. 30 In contrast to miR-let7c, no change of miR-218 was observed in the exosomes isolated from miR-let7c-MSCs, compared to NTC-MSC culture medium (Figure 3b ), confirming that endogenous expression of other miRNAs were not affected.
Next, the endocytosis efficiency of the miR-let7c produced by modified MSC was
examined. An indirect in vitro co-culture assay was established to determine if miR-let7c-MSCs could deliver a significantly increased expression of the target miRNA (let7c) to hours of co-culture, qPCR was performed on NRK52E cells to confirm the successful transfer of let7c miRNA. There was a significant 4.7-fold increase of miR-let7c expression in NRK52E cells co-cultured with miR-let7c MSCs, compared to NTC-MSCs (P<0.0001; Figure 3c ). Endogenous miR-let7c expression in NRK52E co-cultured with
MSCs marginally increased compared to the NRK52E cells without co-culture ( Figure   3c ), suggesting MSCs have endogenous miR-let7c expression as reported previously 16 .
To further verify the exosome function in the delivery of miR-let7c, the exosome inhibitor neutral sphingomyelinase (nSMase2), GW4869, was used to treat the cocultured NRK52E and miR-let7c-MSC or NTC-MSC. There was no difference in miRlet7c expression between the NTC-MSC and miR-let7c-MSC co-cultured NRK52E cells (Figure 3d ), therefore confirming exosomal transfer of miR-let7c.
To visualize exosome delivery between miR-let7c-MSCs and NRK52E cells, cyc3 labelled pre-miRNA control oligos (cyc3-oligo) were transfected into miR-let7c-MSCs followed by intracellular visualization using immunofluorescence microscopy ( Figure   3e ). After 72 hours of indirect co-culture, cyc3-staining was evident in the cytoplasm of NRK52E cells (Figure 3e ). In comparison, the addition of the exosome inhibitor GW4869
abolished the cyc3-staining in NRK52E cells (Figure 3e ), suggesting the function of exosome as a cyc3 vehicle. To confirm this intercellular communication, NRK52E cells were also co-cultured with MSCs without cyc3-oligo transfection and no cyc3 fluorescent A c c e p t e d m a n u s c r i p t labeling was detected (Figure 3f ). This data confirms that miRNA from MSCs can be delivered intercellularly into kidney epithelial cells, and provides important evidence to investigate the anti-fibrotic effect of miR-let7c-MSCs on NRK52E cells.
MSC expressing miR-let7c reduces α-SMA and collagen in NRK52E cells
To determine the efficacy of miR-let7c delivered from engineered MSCs, qPCR was used to determine key genes involved in kidney fibrosis in NRK52E cells in response to TGF-β1. NRK52E cells, with or without the addition of TGF-β1, were co-cultured using 
UUO induced fibrotic-related gene expression is reduced by miR-let7c-MSC treatment
To validate the morphometric analysis, qPCR assessed the relative expression of collagen 
A c c e p t e d m a n u s c r i p t
However, current methods of miRNA delivery including viruses and liposomes prove unsatisfactory due to safety concerns and low efficiency in vivo, respectively. 34 Our data indicates a potential and feasible therapeutic strategy that couples MSCs and miRNA as an effective, specific and efficient delivery anti-fibrotic therapy targeted to kidney injury.
Endogenous miRNAs can be transferred by MSCs via microvesicles and exosomes that act as intercellular communicators. 35 We now report that MSCs, successfully engineered to overexpress miR-let7c, display normal growth characteristics and are able to deliver miRNA through exocytosis using both in vitro and in vivo models of renal fibrosis. Using family members, miR-let7b and miR-let7c, in renal fibrosis resulting from diabetes mellitus. Our previous work reports that miR-let7 regulates TGF-βR1 and TGF-β/Smad signalling and may therefore also regulate the activity of matrix proteins. 8 TGF-β1 is a classical mediator of renal fibrosis and inflammation. 48 Profiling of human proximal tubule kidney-2 (HK2) cell miRNAs demonstrated that miR-let7c was strongly downregulated under fibrotic conditions compared with the levels of other miRNAs. 9 miR-let7
A c c e p t e d m a n u s c r i p t is important in the regulation of cell proliferation, including cancer cells and stem cells 49 and is reduced in idiopathic pulmonary fibrosis.
50, 51
The selective homing of MSCs to the inflammatory site of injury makes specific exosome delivery and transport of miR-let7c using this delivery system particularly attractive. Our results show preferential tracking of MSCs to UUO kidneys following initial entrapment in the lungs, as we have previously reported in other models. 52, 53 MSCs can themselves elicit kidney repair through paracrine and/or endocrine mechanisms and release trophic growth factors that modulate the immune response and consequently mediate repair.
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Interestingly, endogenous miR-let7 expression has been identified in MSCs. 12, 55 Our results also indicate that control NTC-MSCs can repress the 3'UTR expression of TGFβ-R1, which is involved in endogenous miR-let7c secretion. Our in vivo studies showed that administration of NTC-MSCs also reduced kidney damage and collagen accumulation, although these renoprotective benefits were further enhanced following miR-let7c-MSC therapy. Importantly, another pro-inflammatory regulator, MMP9 that has been suggested as a target of miR-let7 was also down-regulated in the in vivo model after delivery of MSCs 56, 57 .
MSCs may provide novel vehicles to deliver miRNA in a site-specific manner, but have the combined benefits of low immunogenicity. 58 Several clinical studies have progressed the use of MSCs as a valuable tool for improving solid organ transplantation without the need for high concentrations of immunosuppressive drugs. 59 The application of MSCs in the treatment of kidney disorders has resulted in no adverse side effects in humans. In summary, our studies show that genetic engineering of MSCs using miR-let7c enables effective antifibrotic effects and a high-efficiency delivery of therapeutic miR-let7c. Of particular relevance, this approach allows for the potential of delivering miRNAs, such as miR-let7c, within exosomes where they can be selectively tracked to damaged kidneys to produce a functional response. The targeted delivery of miR-let7 into the injured kidney in chronic and acute kidney damage is likely to profoundly alter the disease and ameliorate the progression to end-stage renal failure. In the long-term, this innovative therapeutic approach could be applied to other chronic degenerative diseases that culminate in fibrotic injury.
Materials and Methods

Cell culture
Human bone marrow derived MSCs (Tulane University, New Orleans, USA), were maintained in Alpha Minimum Essential Medium (á-MEM; Gibco, Australia) from passage 4 to 10, and supplemented with 16.5% fetal bovine serum (FBS; Atlanta Biologicals, USA), 4mM L-glutamine (Gibco, Australia) and 1% streptomycin sulphate and penicillin (Gibco). The MSCs were characterized for multilineage differentiation potential using a human mesenchymal stem cell functional identification kit (R&D Systems).
A c c e p t e d m a n u s c r i p t
Rat kidney tubular epithelial cells (NRK52E; Sigma ATCC, USA) utilized from passage 34 to 44 were maintained in Dulbecco's Modified Eagle Medium (DMEM; Life Technologies, Australia) supplemented with 10% FBS, 4mM L-glutamine, 1%
streptomycin sulphate and penicillin and cultured with/without TGF-β1 (5ng/ml; R&D Systems). For co-culture studies, NRK52E cells were seeded in 6 well cell culture plates, at a density of 80,000 cells/well. Hanging cell culture inserts (1µ m; Millipore) were positioned above the NRK52E cells and seeded with human MSCs at a density of 30,000 cells/insert. Cells were cultured using MSC media, as previously described.
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Lentiviral transduction of MSCs and cell sorting
RNA duplexes corresponding to short non-coding oligo labeled with Cy3 (Life Technologies) were transfected in MSCs using lipofectamine2000 (Lipofectamine, Life Technologies) as previously described.
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The transfection efficiency using lipofectamine2000 was approximately 70%, as visualized using fluorescence microscopy.
SMARTchoice shMIMIC Lentiviral microRNA expressing pre-miR-let7c and NTC pre- 
Preparation of exosomes
MSCs were tranduced with NTC miRNA or miR-let7c and were maintained in MSC medium using exosome-free FBS. Following four days of incubation, exosomes were isolated from the supernatants of the MSC cultures using the exosome precipitation solution, ExoQuick, as previously described (System Bioscience, Mountain View, CA).
RNA was isolated using a Qiagen RNA extraction kit (Qiagen, Valencia, CA).
RNA extraction and real-time PCR
The RNAs were isolated using Qiagen RNA extraction kit (Qiagen, Valencia, CA)
according to manufactures instructions. 
A c c e p t e d m a n u s c r i p t microRNA assay
For microRNA analysis, cDNA synthesis qPCR was performed using TaqMan microRNA assays according to the manufacturer's recommendations (Applied Biosystems, Foster City, CA). Experimental groups were in replicates of six and normalized to U6 snRNA for rat and mouse samples, respectively. Each experiment was conducted three times.
3'-UTR-luciferase-reporter analyses
The 3'UTR luciferase reporter assays were performed as we have previously described. brightfield and polarized microscopy as described previously.
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Statistical analysis
Values are shown as means±SEM, unless otherwise specified. GraphPad Prism 
